Fate of Trump's Part B drug cost plan may depend on Dems winning House

Modern Healthcare: The Trump administration's bold proposal to peg Medicare Part B drug payments to the much lower prices paid in other advanced countries surprised many. But veteran policywatchers say they'd be stunned if the plan goes anywhere given pharma's deep pockets, congressional Republicans' coolness to the proposal and congressional Democrats' skepticism.

Meanwhile, physician and patient advocacy groups, which helped kill a somewhat similar Obama administration proposal two years ago, were guarded in their reactions pending release of further details about President Donald Trump's plan.

Read article